Fusion Pharmaceuticals Inc. is a clinical-stage oncology enterprise focused on creating precise radiopharmaceutical therapies. The company utilizes its groundbreaking Targeted Alpha Therapies platform, which incorporates its exclusive Fast-Clear linker technology. This innovative system enables the attachment of alpha particle-emitting isotopes to diverse targeting molecules, facilitating the targeted delivery of these potent payloads directly to cancerous growths.